Drug Patent Watch
APRIL 13, 2024
DEXILANT SOLUTAB (dexlansoprazole) Takeda pharms usa Patent: 8,784,885 Expiration: Apr 15, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact… Source
Drug Patent Watch
APRIL 13, 2024
This chart shows the pharmaceutical companies with the most cream dosed drugs. For a different perspective, see the most popular dosage types.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
APRIL 13, 2024
Annual Drug Patent Expirations for ADVAIR+HFA Advair Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from three suppliers.
Drug Patent Watch
APRIL 13, 2024
Annual Drug Patent Expirations for GOCOVRI Gocovri is a drug marketed by Adamas Operations and is included in one NDA. It is available from one supplier.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Drug Patent Watch
APRIL 13, 2024
Annual Drug Patent Expirations for VOSEVI Vosevi is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier.
Drug Patent Watch
APRIL 13, 2024
Annual Drug Patent Expirations for DAURISMO Daurismo is a drug marketed by Pfizer and is included in one NDA. It is available from one supplier.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Drug Patent Watch
APRIL 13, 2024
Annual Drug Patent Expirations for TYRVAYA Tyrvaya is a drug marketed by Oyster Point Pharma and is included in one NDA. It is available from one supplier.
Drug Patent Watch
APRIL 13, 2024
Annual Drug Patent Expirations for RECORLEV Recorlev is a drug marketed by Strongbridge and is included in one NDA. It is available from one supplier.
Expert insights. Personalized for you.
59 
Let's personalize your content